TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
This Quarter Return
+20.64%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.64B
AUM Growth
+$2.64B
(+15%)
Cap. Flow
-$3.06M
Cap. Flow
% of AUM
-0.12%
Top 10 Holdings %
Top 10 Hldgs %
38.92%
Holding
218
New
26
Increased
62
Reduced
55
Closed
4
Top Buys
| 1 |
Regeneron Pharmaceuticals
REGN
|
$15.6M |
| 2 |
Johnson & Johnson
JNJ
|
$14.4M |
| 3 |
Cigna
CI
|
$13.4M |
| 4 |
Abbott
ABT
|
$13M |
| 5 |
Milestone Pharmaceuticals
MIST
|
$11.2M |
Top Sells
| 1 |
CELG
Celgene Corp
CELG
|
$146M |
| 2 |
UnitedHealth
UNH
|
$26M |
| 3 |
Humana
HUM
|
$10.7M |
| 4 |
Intuitive Surgical
ISRG
|
$9.93M |
| 5 |
Zoetis
ZTS
|
$7.76M |
Sector Composition
| 1 | Healthcare | 94.16% |
| 2 | Real Estate | 3.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
GWPH
101
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $5.24M | 0.2% | 50,101 -14,398 | -22% | -$1.51M |
|
102
uniQure
QURE
$896M
| $5.1M | 0.19% | 71,191 +27,342 | +62% | +$1.96M |
|
103
Xencor
XNCR
$580M
| $5.1M | 0.19% | 148,231 | – | – |
|
104
Smith & Nephew
SNN
$16.3B
| $4.79M | 0.18% | 99,560 -22,085 | -18% | -$1.06M |
|
105
PTC Therapeutics
PTCT
$3.92B
| $4.77M | 0.18% | 99,327 -49,108 | -33% | -$2.36M |
|
106
United Therapeutics
UTHR
$13.8B
| $4.77M | 0.18% | 54,094 | – | – |
|
107
Rocket Pharmaceuticals
RCKT
$354M
| $4.72M | 0.18% | 207,555 | – | – |
|
108
iShares Biotechnology ETF
IBB
$5.6B
| $4.68M | 0.18% | 38,834 +19,920 | +105% | +$2.4M |
|
109
CRISPR Therapeutics
CRSP
$4.71B
| $4.64M | 0.18% | 76,222 -25,114 | -25% | -$1.53M |
|
|
XLRN
110
DELISTED
Acceleron Pharma Inc.
XLRN
| $4.58M | 0.17% | 86,313 | – | – |
|
111
Ardelyx
ARDX
$1.53B
| $4.56M | 0.17% | 607,698 +25,000 | +4% | +$188K |
|
112
Acadia Healthcare
ACHC
$2.12B
| $4.53M | 0.17% | 136,200 | – | – |
|
|
BMY.RT
113
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
| $4.44M | 0.17% | +1,473,710 | New | +$4.44M |
|
114
Healthpeak Properties
DOC
$12.5B
| $4.43M | 0.17% | 128,537 +83,037 | +182% | +$2.86M |
|
|
ARQL
115
DELISTED
Arqule Inc
ARQL
| $4.4M | 0.17% | 220,409 +144,355 | +190% | +$2.88M |
|
116
Editas Medicine
EDIT
$231M
| $4.38M | 0.17% | 147,939 | – | – |
|
117
Tenet Healthcare
THC
$16.3B
| $4.31M | 0.16% | 113,436 -27,700 | -20% | -$1.05M |
|
118
ResMed
RMD
$40.2B
| $4.3M | 0.16% | 27,775 -9,335 | -25% | -$1.45M |
|
119
Ligand Pharmaceuticals
LGND
$3.15B
| $4.27M | 0.16% | 40,955 -3,100 | -7% | -$323K |
|
|
ICPT
120
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $4.27M | 0.16% | 34,414 | – | – |
|
121
Ultragenyx Pharmaceutical
RARE
$2.89B
| $4.16M | 0.16% | 97,480 | – | – |
|
122
Bausch Health
BHC
$2.74B
| $4.15M | 0.16% | 138,812 -30,000 | -18% | -$898K |
|
123
Takeda Pharmaceutical
TAK
$47.3B
| $4.15M | 0.16% | 210,146 | – | – |
|
124
Alkermes
ALKS
$4.78B
| $4.04M | 0.15% | 198,048 | – | – |
|
125
Apellis Pharmaceuticals
APLS
$3.48B
| $4.01M | 0.15% | 130,999 +32,215 | +33% | +$986K |
|